An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in <i>in vitro</i> Inflammatory Bowel Disease Models

Koon Jiew Chua(National University of Singapore), Hua Ling(National University of Singapore), In Young Hwang(National University of Singapore), Hui Ling Lee(National University of Singapore), John C. March(Cornell University), Yung Seng Lee(National University of Singapore), Matthew Wook Chang(National University of Singapore)
ACS Biomaterials Science & Engineering
November 18, 2022
10.1021/acsbiomaterials.2c00202
Cited by 28Open Access
Full Text

Abstract

IBD models, demonstrating their potential as live biotherapeutics for IBD immunotherapy.

Related Papers

No related papers found

Powered by citation graph analysis